Eton Pharmaceuticals, Inc.宣布通过收购Hemangeol®（盐酸普萘洛尔）口服溶液在美国的商业化权利，进一步扩大其在罕见病领域的业务布局。此次交易将强化该公司在专科治疗市场的产品管线，为罕见病患者提供更多治疗选择。
Eton Pharmaceuticals, Inc.宣布通过收购Hemangeol®（盐酸普萘洛尔）口服溶液在美国的商业化权利，进一步扩大其在罕见病领域的业务布局。此次交易将强化该公司在专科治疗市场的产品管线，为罕见病患者提供更多治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.